Latest News - Aerpio Therapeutics

Wednesday, November 15, 2017 | Management/Leadership, Aerpio Therapeutics

Aerpio Pharmaceuticals Announces Appointment of Michael Rogers as Chief Financial Officer

Aerpio Pharmaceuticals announced that Michael Rogers has been appointed Chief Financial Officer effective as of November 15, 2017. Mr. Rogers has more than 25 years of experience in the biopharmaceuti…

Read the full story

Thursday, June 29, 2017 | Clinical Trials, Aerpio Therapeutics

Aerpio Announces Initiation of Patient Dosing in the TIME-2b Study, a Phase 2b Clinical Trial of AKB-9778 in Patients with DR

Aerpio Pharmaceuticals announced the initiation of patient dosing in the company’s TIME-2b study, a phase 2b clinical trial designed to assess the efficacy and safety of Aerpio’s lead cand…

Read the full story

Friday, March 17, 2017 | Earnings & Financials, Retina, Aerpio Therapeutics

Aerpio Pharmaceuticals Raises $40 Million

Aerpio Pharmaceuticals, a biopharmaceutical company focused on advancing first-in-class treatments for ocular diseases, announced the successful completion of its reverse merger transaction with Aerpi…

Read the full story

Tuesday, June 14, 2016 | Clinical Trials, Aerpio Therapeutics

Aerpio Therapeutics Reports Positive Clinical Results from the Phase 2a Study of AKB-9778 in DME: The TIME-2 Trial

Aerpio Therapeutics announced that clinical data from the company’s phase 2a study of its lead candidate, AKB-9778, for the treatment of patients with DME, have been published in an article titl…

Read the full story

Thursday, February 11, 2016 | Clinical Trials, Aerpio Therapeutics

Aerpio Therapeutics Announces Presentation of Positive Results of AKB-9778 in Patients with Diabetic Retinopathy from TIME-2 Phase 2a Study

Aerpio Therapeutics announced promising results in diabetic retinopathy from the company’s phase 2a study (TIME-2) of its lead candidate, AKB-9778, a first-in-class Tie2 activator, according to …

Read the full story